SEC Form 4 · accession 0001209191-16-155530
ACORDA THERAPEUTICS INC · ACOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ron Cohen
Officer — President and CEO · Director
Period of report
Dec 14, 2016
Accepted (ET)
Dec 16, 2016 · 8:08 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001008848
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 14, 2016 | M | 40,172 | $15.49 | A | 519,860 | D | |
| Common StockF1,F2 | Dec 14, 2016 | S | 39,764 | $20.746 | D | 480,096 | D | |
| Common StockF1 | Dec 14, 2016 | S | 408 | $21.35 | D | 479,688 | D | |
| Common StockF3 | holding | — | — | — | 42,940 | I | Beneficial Ownership in Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F4 | $15.49 | Dec 14, 2016 | M | 40,172 | D | — | Dec 21, 2016 | Common Stock | 40,172 | 0 | D |
Explanation of responses
- F1Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2016 on the expiration date reported within Table II unless exercised.
- F2The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.30 to $21.25 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3These shares are held in a grantor retained annuity trust, which was established by the reporting person and of which he is the sole trustee.
- F4The shares subject to these options vested in installments and were fully vested on January 1, 2011.